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ABSTRACT: Protein kinase inhibitors are proving highly effective in helping treat a number of non-
communicable diseases driven by aberrant kinase signaling. They are also extremely valuable as 
chemical tools to help delineate cellular roles of kinase signaling complexes. The binding of small 
molecule inhibitors induces conformational effects on kinase dynamics; evaluating the effect of 
such interactions can assist in developing specific inhibitors and is deemed imperative to under-
stand both inhibition and resistance mechanisms. Using gas-phase ion mobility-mass spectrome-
try (IM-MS) we characterized changes in the conformational landscape and stability of the protein 
kinase Aurora A (Aur A) driven by binding of the physiological activator TPX2 or small molecule 
inhibition. Aided by molecular modeling, we establish three major conformations: one highly-
populated compact conformer similar to that observed in most crystal structures, a second highly-
populated conformer possessing a more open structure that is infrequently found in crystal struc-
tures, and an additional low-abundance conformer not currently represented in the protein data-
bank. Comparison of active (phosphorylated) and inactive (non-phosphorylated) forms of Aur A 
revealed that the active enzyme has different conformer weightings and is less stable than the in-
active enzyme. Notably, inhibitor binding shifts conformer balance towards the more compact con-
figurations adopted by the unbound enzyme, with both IM-MS and modelling revealing inhibitor-
mediated stabilisation of active Aur A. These data highlight the power of IM-MS in combination 
with molecular dynamics simulations to probe and compare protein kinase structural dynamics 
that arise due to differences in activity and as a result of compound binding. 
Introduction 
Protein kinase-mediated phosphorylation permits dynamic 
regulation of protein function and is an essential mechanism for 
modulating a host of fundamental biological processes. Inhibi-
tion of these enzymes by small molecules can serve both as a 
research tool to help understand cell signalling mechanisms, 
and also to help treat diseases such as cancer, inflammatory dis-
orders and diabetes (1), where protein phosphorylation is of-
ten dysregulated.  
Protein kinases consist of an N-terminal and a C-terminal lobe, 
connected via a flexible hinge region, which forms the 
conserved ATP-binding site. The activation loop in protein 
kinases is 20–30 residues long with a conserved DFG motif at 
the beginning, typically extending out to an invariant APE motif. 
Activation loops of active kinases are mobile, and help form a 
cleft that enables substrates to bind. Substrates are then 
positioned adjacent to the HRD motif, where the catalytic Asp 






The ATP-binding sites of members of the kinase superfamily 
share a high degree of sequence conservation, which has made 
the development of highly selective ATP-competitive inhibitor 
compounds extremely challenging, and usually requires the ex-
ploitation of unique, often subtle, structural deviations in indi-
vidual enzymes. Understanding the selectivity and specificity of 
these small molecule inhibitors towards target enzymes is crit-
ical for correct interpretation of data arising from their use, due 
to the likelihood of ‘off-target’ effects driven through similar ki-
nase conformations that exist across members of the evolution-
ary-related kinome (3). 
Protein kinase inhibitors can be broadly classified based on 
their ability to bind to different regions within the enzyme su-
perfamily, or to a specific conformational state. In catalytically 
active kinases, the activation loop usually exists in a ‘DFG-in’ 
conformation, orientating the conserved DFG motif to support 
metal binding as the DFG-Phe contacts the C-helix of the N-ter-
minal lobe. In contrast, a kinase occupying a ‘DFG-out’ confor-
mation is less able to bind ATP, since the Phe partially occludes 
the metal:nucleotide binding site and exposes a C-helix pocket, 
rendering it catalytically inactive (4). The majority of kinase 
small molecule inhibitors function by disrupting the ability of 
kinases to bind to- and/or hydrolyse ATP and therefore block 
phosphate transfer to  protein substrates, either by competing 
directly with ATP binding, or by locking the enzyme in an 
‘inactive’ conformation.  
Critically, much of our current understanding of kinase 
inhibitor binding modes comes from X-ray crystallography of 
kinase:inhibitor complexes. While ‘type I’ inhibitors, such as 
staurosporine and dasatanib, competitively bind to the ATP-
binding site of kinases in the active ‘DFG-in’ conformation, ‘type 
II’ inhibitors like imatinib are ‘mixed mode’, contacting both the 
ATP binding site and an adjacent hydrophobic groove that is 
only accessible in the ‘DFG-out’ conformation, which serves to 
lock the target kinase into an inactive state (5). The ability of 
small molecules to discriminate between, and selectively bind 
to, kinases in various active and inactive structural orientations 
has been used as a defining tool to group classes of inhibitor 
compounds (6). However, in addition to significant diversity in 
the DFG-in and (in particular) DFG-out structures of multiple 
kinases, a variety of kinases exist in which the Phe residue of 
the DFG motif can adopt an ‘intermediary’ orientation between 
the typical DFG-in and DFG-out conformation, termed DFG-up 
or DFG-inter (2). 
Characterizing the effects of small molecule inhibitors on the 
structure and catalytic activity of protein kinase targets, and 
the influence of post-translational modifications (PTMs; typi-
cally activating phosphorylation) on these interactions pro-
vides fundamental mechanistic knowledge for drug discovery 
and helps iterative drug design. However, limitations  often 
arise with crystallographic structural studies, with some pro-
tein being intransigent to crystallisation (7). Moreover, the 
analysis of solid-state crystals hampers the ability to define and 
understand conformational flexibility and protein dynamics in 
both the absence and presence of bound small molecules. 
Consequently, analysis of protein crystal structures may only 
permit limited exploration of the conformational space adopted 
by kinases in solution. NMR, while useful for examining 
conformational dynamics of purified proteins, requires much 
more significant (multi-milligram) amounts of pure material, 
and obtaining a full atomic map for larger proteins or 
complexes greater than ~50 kDa remains a challenge (8). 
Native mass spectrometry (MS), in which liquid-phase samples 
are subjected to electrospray ionisation (ESI) under non-
denaturing conditions to more closely mimic their 
physiological environment, is increasingly being used to 
investigate the topology of intact protein complexes (9). Under 
carefully controlled conditions (pH, ionic strength, applied 
voltage, gas-pressure), the folded native state of the analyte 
protein (and ligand) complexes can be maintained (10). Native 
MS is primarily used to define the molecular mass of protein 
complexes (and component stoichiometry), compare the 
relative dissociation contant (KD) of ligand binding (11-14), and 
in a broad sense, the degree of protein ‘disorder’ (15). When 
used in combination with ion mobility (IM) spectrometry, 
native MS (IM-MS) can reveal structural changes that arise due 
to ligand binding or protein modification as well as 
interrogating protein conformational dynamics, stability and 
unfolding transitions (16). When appropriately calibrated, 
native IM-MS can also be used to determine the rotationally 
averaged collision cross-section (CCS) of proteins and their 
complexes, empirical information that can be compared both 
with other structural measurements, and theoretical 
calculations (13) to understand the effects of PTMs or small 
molecule binding on protein structure and dynamics.    
The Ser/Thr protein kinase Aurora A (Aur A) is classically as-
sociated with mitotic entry and plays critical roles in centro-
some maturation and separation (17). In early G phase of the 
cell cycle, Aur A is recruited to the centrosomes where it facili-
tates spindle assembly (18, 19). Later, Aur A microtubule asso-
ciation and activation requires binding of the Eg5-associated 
microtubule factor TPX2 (20-22). The N-terminus of TPX2 
binds to the Aur A catalytic domain, inducing conformational 
changes in the kinase which both enhances its autophosphory-
lation at Thr288 within the activation loop, and shields the ac-
tivating T-loop phosphorylation site from phosphatases such as 
PP6 (23-25). Overexpression of Aur A results in mitotic abnor-
malities and the development of tetraploid cells (26). While el-
evated levels of Aur A are broadly associated with a range of 
cancers, including breast, colorectal, ovarian and pancreatic 
(27), depletion of Aur A activity leads to abnormalities in mi-
totic spindle assembly, which results in a spindle checkpoint-
dependent mitotic arrest (28-31). More recently, catalytically-
independent roles for Aur A in different phases of the cell cycle  
have also been described (30, 32-35). 
A huge number of Aur A inhibitors have been developed and 
reported in the last two decades (36), many of which target all 
three members of the Aurora kinase family, most notably the 
well-studied pan Aur inhibitor, VX-680/tozasertib (31, 37). In-





have also been developed by targeting specific amino acid dif-
ferences in the ATP site that occur between Aur A and Aur B/C 
(38-40). For example, Alisterib (MLN8237) is a selective Aur A 
inhibitor that alongside the earlier tool compound MLN8054 
(41, 42) has been characterised using a variety of in vitro and in 
vivo pre-clinical models (43). Importantly, MLN8237 has been 
phenotypically target-validated in cells with drug-resistant Aur 
A alleles (34, 42). It has also been shown to inhibit proliferation 
in a number of human tumour cell lines, such as ovarian, pros-
tate, lung and lymphoma cells, and has proven effective in pae-
diatric-type cancer models, including neuroblastoma, acute 
lymphoblastic leukaemia and Ewing sarcoma cell lines (44). 
MLN8237 has been assessed in Phase I and II clinical trials for 
haematological malignancies, patients with advanced solid tu-
mours and children with refractory/recurrent solid tumours 
(45, 46). 
To better understand the effects of small molecule binding on 
Aur A, Levinson and colleagues recently reported a study to 
evaluate the conformational effects of a panel of clinically 
relevent Aur kinase inhibitors across different activation states 
of Aur A using time-resolved Förster resonance energy transfer 
(TR-FRET). Using this approach, they were able to track 
dynamic structural movements of the kinase activation loop, 
distinguishing between inhibitors that induce DFG-in states 
from compounds that promote other conformations (DFG-
out/DFG-up/DFG-inter). The TR-FRET data was consistent 
with equilibrium shifts towards three distinct conformational 
groups, including DFG-in state, DFG-out state and ’unique’ 
structural states (47). 
In this study, we employ IM-MS to explore the effects of inhibi-
tor binding on the conformational landscape, dynamics and sta-
bility of two variants of the Aur A kinase domain; a catalytically 
active hyperphosphorylated protein, and an inactive non-phos-
phorylated version created by a point mutation within the DFG 
motif (D274N). These studies reveal marked differences in the 
conformational landscape adopted by active and inactive Aur A 
and also when complexed with inhibitors, with the active form 
presenting a shift in the conformer balance towards a less con-
formationally flexible configuration. Crucially, our CIU data also 
suggest that chemical inhibitors induce stabilisation of both hy-
per- and non-phosphorylated Aur A, whilst revealing interme-
diate unfolding transition differences that correlate with previ-
ously reported DFG in/out/up classifications with distinct com-
pounds. Together, our biophysical data demonstrate the ap-
plicability of IM-MS for distinguishing modes of inhibitor bind-
ing to kinases that could be extendable to other members of the 
highly druggable superfamily. 
 
Materials and Methods 
Protein purification 
6His-N-terminally tagged human Aur A (122-403) wild-type 
(WT) or D274N were individually expressed from a pET30-TEV 
vector in BL21 (DE3) pLysS Escherichia coli (Novagen), with 
protein expression being induced with 0.4 mM IPTG for 18 h at 
18 °C. E. coli pellets were lysed in 100 mL of ice cold lysis buffer 
(50 mM Tris-HCl pH 7.4, 10% glycerol, 300 mM NaCl, 10 mM 
imidazole, 1 mM DTT, 100 mM EDTA, 100 mM EGTA, protease 
inhibitor tablet (Roche)). The lysed cells were then sonicated 
on ice using a 3 mm microprobe attached to a MSE Soniprep 
150 plus motor unit at an amplitude of 16 microns in 30 second 
intervals. Samples were centrifuged for 1 h at 8 °C (43,000 x g) 
to pellet the cellular debris and then filtered through a 0.22 µm 
filter. His-tagged Aur A was separated from clarified bacterial 
cell lysate using a Nickel HisTrap HP column, pre-equilibrated 
in wash buffer (50 mM Tris-HCI pH 7.0, 10% glycerol, 300 mM 
NaCl, 20 mM imidazole, 1 mM MgCl2). After loading the cell ly-
sate, the column was washed with 10 mL of wash buffer, fol-
lowed by 10 mL of elution buffer (50 mM Tris-HCI pH 7.0, 10% 
glycerol, 300 mM NaCl, 500 mM imidazole, 1 mM MgCl2, 1 mM 
DTT) and the His-tag cleaved by addition of 25 µg of TEV prote-
ase and incubation for 18 h at 4 °C. Subsequently, Aur A was 
further purified using a Superdex 200 16 600 column (GE 
Healthcare) attached to an AKTA FPLC system and a Frac-920 
(GE Healthcare), which was equilibrated in filtered and de-
gassed gel filtration buffer (20 mM Tris pH 7.0, 10% glycerol, 
200 mM NaCl, 40 mM imidazole, 5 mM MgCl2, 1 mM DTT). Aur 
A-containing fractions were pooled and passed through a 
HisTrap column to remove residual non-TEV cleaved material. 
Samples were stored in small aliquots at -80 °C prior to further 
analysis. 
Native Ion Mobility-Mass Spectrometry 
Immediately prior to native MS analysis, purified Aur A pro-
teins were buffer-exchanged into 150 mM NH4OAc using an 
Amicon spin filter (10 kDa cut-off). Spin columns were pre-
washed with 500 µL of 150 mM NH4OAc prior to the addition of 
protein and spun 3x 10 min at 13,000 RPM. Following the final 
spin, the filter was inverted into a new collection tube and spun 
for 2 min at 3,000 RPM to collect the protein. Protein concen-
tration was calculated using a NanoDrop spectrophotometer at 
a wavelength of 280 nm and adjusted to 5 µM for MS analysis. 
To evaluate the effect of small molecule binding, Aur A proteins 
were incubated with 4% DMSO (vehicle control), or a 10x molar 
excess of inhibitor or TPX2 activating 43mer peptide (H2N-
MSQVKSSYSYDAPSDFINFSSLDDEGDTQNIDSWFEEKANLEN-
CONH2, Pepceuticals) and equilibrated for 10 min at room tem-
perature prior to IM-MS analysis. Ion mobility-mass spectrom-
etry data was acquired on a Waters Synapt G2-Si instrument 
operated in ‘resolution’ mode.  Proteins were subject to nano-
electrospray ionization (nESI) in positive ion mode (at ~2 kV) 
with a pulled nanospray tip (World Precision Instruments 
1B100-3) prepared as detailed in (48). Ions of interest were 
mass selected in the quadrupole prior to IMS. The pressure in 
the TWIMS cell was set at 2.78 mbar (nitrogen), with an IM 
wave height of 23 V, a wave velocity of 496 m/s and a trap bias 
of 33.  
Collision-induced unfolding 
For collision-induced unfolding (CIU) experiments, the 11+ 





of bound inhibitor was quadrupole-isolated and subjected to 
collisional activation by applying a CID activation in the ion trap 
of the TriWave. The activation voltage was increased gradually 
from 16 to 34 V in two-volt intervals before IMS measurement. 
CIU was carried out with a travelling wave height of 27 V, ve-
locity of 497 m/s and a trap bias of 35.  
Phosphosite mapping 
Purified Aur A was buffer-exchanged into 100 mM ammonium 
bicarbonate, reduced with 4 mM DTT (30 min, 60 °C), and re-
duced Cys residues alkylated with 7 mM iodoacetamide (45 
min, dark at room temperature), as described previously (49). 
Proteins were then digested with trypsin (2% (w/w) Promega) 
for 18 h at 37 °C. RapiGest SF hydrolysis was carried out using 
1% TFA (1 h, 37 °C, 400 RPM), prior to LC/MS/MS analysis (49). 
Phosphopeptide data was processed using Thermo Proteome 
Discoverer (2.4) and MASCOT (2.6). Raw mass spectrometry 
data files were converted to mzML format to enable processing 
with Proteome Discoverer. Data was searched against a human 
UniProt Aur A database limited to residues 122-403 or the 
D274N mutation. Processing settings were set as follows: dy-
namic modifications – Phospho (S/T/Y), maximum missed 
cleavages – 2, MS1 tolerance – 10 ppm and MS2 mass tolerance 
– 0.01 Da. 
CCS Calibration and IM-MS Data Analysis 
Calibration of the TriWave device was performed using β-lac-
toglobulin (Sigma L3908), cytochrome c (Sigma C2506) and bo-
vine serum albumin (Sigma A2153) as previously described 
(50). All data were processed using MassLynx (v. 4.1) and 
Matlab (2018a) to determine collision cross section (CCS) val-
ues. Gaussian fitting was performed in Matlab (Version 
R2018a), using code minimally adapted from peakfit.m (51)  
(see supplementary information for detail). Scatter plots of 
TWCCS N2>He (nm2) values versus CCS distribution (CCSD) (nm2) 
were generated using ggplot in RStudio. CIU unfolding plots 
were generated using CIUSuite 2 (52).  
Western Blotting 
Western blotting was carried out using standard procedures. 
Nitrocellulose membranes were blocked in 5% milk powder 
(Marvel) in Tris-buffered saline and 0.1% Tween 20 (TBST) (20 
mM Tris pH 7.6, 137 mM NaCl, 0.1% Tween-20 (v/v)) for 1 h at 
room temperature on a shaking rocker. All antibodies were pre-
pared in 5% milk TBST. Anti-phospho Aur A (T288) (Cell Sig-
nalling Technologies 2914) was used at 1:5000 dilution and in-
cubated with the membrane for 18 h at 4 °C, as described pre-
viously (53). Secondary anti-rabbit antibody (1:5000) was in-
cubated for 1 h at room temperature. X-ray film was exposed to 
the membrane following application of Immobilon Western 
Chemiluminescent HRP Substrate (Millipore) developing rea-
gent. The films were developed using an ECOMAX X-ray film 
processor (Protec). 
Protein kinase activity assays 
In vitro peptide-based Aur A assays were carried out using a 
Caliper LapChip EZ Reader platform (Perkin Elmer), which 
monitors real-time phosphorylation-induced changes in the 
mobility of a fluorescently labelled Kemptide peptide substrate 
(5’-FAM-LRRASLG-CONH2) (54). The activity of both WT and 
D274N Aur A variants (10 ng) was evaluated by incubation with 
1 mM ATP and phosphorylation of 2 µM fluorescent peptide 
substrate in 50 mM HEPES (pH 7.4), 0.015% (v/v) Brij-35, 1 
mM DTT and 5 mM MgCl2. The activity of Aur A after incubation 
with TPX2 peptide (5 µM) was determined using a TPX2 con-
centration range of 0.0004 - 40 µM. To confirm loss of catalytic 
activity, D274N Aur A was also assayed with 40 µM TPX2 pep-
tide. Data was plotted as % peptide conversion (phosphoryla-
tion) over a linear real-time scale, using GraphPad Prism soft-
ware as described in (55). 
Differential Scanning Fluorimetry (DSF) assays 
Thermal shift assays were performed using a StepOnePlus 
Real-Time PCR machine (Life Technologies) with Sypro-Orange 
dye (Invitrogen) and thermal ramping (0.3 °C per min between 
25 and 94 °C). All proteins were diluted to 5 μM in 50 mM Tris–
HCl (pH 7.4) and 100 mM NaCl in the presence of 40 µM inhibi-
tor [or 4% (v/v) DMSO as vehicle control concentration], 1 mM 
ATP and/or 10 mM MgCl2. Data was processed using the Boltz-
mann equation to generate sigmoidal denaturation curves, and 
average Tm/ΔTm values were calculated using GraphPad Prism 
software, as previously described (56). 
Molecular modeling 
Missing parts of the Aur A sequence were modelled into crystal 
structures using the PyMod plugin (57) in PyMOL (58). Homol-
ogy models of the full 122–403 catalytic domain sequence 
(equivalent to the catalytic domain) were built using 
MODELLER (59) based on the following Aur A crystal struc-
tures: 1MUO, 1OL5, 1OL6, 1OL7, 2WTV (chain A and B), 3E5A, 
4C3P, 4CEG, 4J8M, 4JBQ, 5EW9, 5G1X, 5L8K, 5ODT, 6HJK. 
Where present, phosphorylated residues and the D274N muta-
tion were accounted for, but otherwise the amino acid se-
quence was the same as UniProt human Aur A accession 
O14965. All other bound proteins or ligands were removed. 
The MODELLER loop modelling function in PyMod was then 
used to build ten improved Aur A models, allowing only the 
newly added residues of the N- and C-termini (and any new A-
loop residues) to change. The model with the lowest ‘objective 
function’ and without obvious new contacts made with the rest 
of the protein, was chosen as the starting structure for model-
ling (30). All-atom simulations were performed with the 
CHARMM36m force field (60) using NAMD (61). Inputs for 
NAMD simulations were generated using CHARMM-GUI (62) 
based on the PYMOD generated models. Phosphorylated resi-
dues use the doubly-deprotonated Thr patch (THPB). N- and C-
termini were uncapped. The protein was solvated in a rectan-
gular waterbox with a minimum distance of 10 Å between the 
protein and the box edge (~20,000 TIP3P water molecules). Cl– 
ions were added to neutralise the protein. Solvated structures 
were first subjected to 10,000 conjugate gradient energy-mini-
mization steps. Prior to the collection of trajectory data, a heat-





to 300 K over 60,000 steps and a short pre-equilibration at 300 
K for 125,000 steps, were used. The time step of 2 fs was used 
throughout. Trajectory frames were recorded every 5000 steps 
(10 ps) and simulations ran for >300 ns with temperature con-
trolled at 300 K and pressure at 1 atm using Langevin dynam-
ics. 
Gō-like models and potentials were generated from all-atom in-
itial structures using the MMTSB web service 
(https://mmtsb.org/webservices/gomodel.html) (63, 64). MD 
simulations of Gō-like models were carried out using Langevin 
dynamics and the CHARMM package, version 44/45 (65). The 
timestep was 10 or 15 fs. Simulations across a range of different 
temperatures were performed to gauge where the unfolding 
transition occurs then production simulations were performed 
below this temperature. 
Simulation trajectories were processed and analysed using 
Wordom (66). The protein component of the system was iso-
lated and aligned, and individual trajectory frames extracted 
for CCS measurements. IMPACT (67) was used to estimate CCS 
values for protein structures. The default atomic radii and con-
vergence parameters were used for all-atom simulations. For 
Gō-like models, atomic radii were estimated to be the average 
distance between each CA atom (3.8 Å). This provided reason-
able comparison with the all-atom simulation results. In all 
cases the raw IMPACT CCS value based on projection approxi-
mation (rather than the recalibrated TJM value) was used, as 
this provided much better comparison with experimental data 
for Aur A models and for a bovine serum albumen test model. 
Clustering of Gō-like model conformers was performed using a 
15-Å RMSD cut-off value between clusters. Native contact frac-
tions in Gō-like models were calculated as described by (68) us-
ing a low temperature (250 K) simulation to define native con-
tacts distances at 80% occupancy. 
 
Results and Discussion 
WT but not D274N Aur A is hyperphosphorylated and cata-
lytically active  
To evaluate the effects of phosphorylation and small molecule 
binding on the conformational landscape, dynamics and flexi-
bility of Aur A, we expressed and purified two well-studied Aur 
A catalytic domain (amino acids 122-403) variants from E. coli: 
a wild-type (WT) active version that extensively auto-phos-
phorylates during exogenous expression (and exhibits reduced 
electrophoretic mobility dependent on phosphorylation during 
SDS-PAGE), and a non-catalytically active variant (D274N), in 
which the essential DFG motif Asp is replaced with Asn (Supp. 
Fig. 1A) (20). MS/MS-based phosphorylation site mapping of 
tryptic peptides from E. coli expressed WT Aur A (122-403) re-
vealed at least 6 sites of autophosphorylation (Fig. 1A), includ-
ing Thr288, which lies in the kinase activation loop and is the 
classical biomarker for Aur A catalytic activity (23, 49, 69, 70). 
No auto-phosphorylation sites were observed in D274N Aur A, 
and this was confirmed by immunoblotting with a phosphospe-
cific antibody against pThr288 (Supp. Fig. 1B). Evaluation of en-
zymatic activity of WT and D274N Aur A, confirmed that WT, 
but not the D274N variant of Aur A, exhibited robust catalytic 
activity towards the substrate peptide in the presence of ATP 
and Mg2+ (Fig. 1B).  
The thermal unfolding profile of WT Aur A, reported as the Tm 
value measured by differential scanning fluorimetry (DSF), in-
creased markedly in the presence of Mg2+/ATP (+8.3 °C), which 
is indicative of tight ATP binding, as previously reported (71). 
In contrast, there was negligible change (+0.1 °C) in the calcu-
lated Tm of D274N Aur A under the same conditions (Fig. 1C, D), 
consistent with the inability of this protein to co-ordinate 
Mg2+/ATP. Stabilisation was greatly reduced for the WT protein 
in the presence of ATP alone (ΔTm = +2.5 °C), which is support-
ive of previous studies showing that Mg2+ is required for high-
affinity binding of ATP to Aur A (71). WT Aur A demonstrated a 
lower melting temperature in comparison to D274N Aur A, sug-
gesting that the inactive D274N Aur A protein is also more sta-
ble than the active WT form (Fig. 1C, D).  
 
Figure 1. Wild-type (WT) hyperphosphorylated Aur A (122-403) is 
less thermodynamically stable than a catalytically inactive non-
phosphorylated D274N Aur A (122-403) variant. A) DSF thermal 
stability assay with 5 µM Aur A (black), in the presence of 1 mM ATP 
(blue), 10 mM MgCl2 (green), or 1 mM ATP + 10 mM MgCl2 (red). B) Dif-
ference in melting temperature (ΔTm) compared with buffer control is 
presented for both WT and D274N Aur A (122-403).  
 
Active hyperphosphorylated Aur A is less stable, and less 
conformationally dynamic than the inactive enzyme 
To assess the effects of phosphorylation on the structure and 
conformational flexibility of Aur A, we analysed the hyperphos-
phorylated WT and the non-phosphorylated D274N proteins 
by native IM-MS, using travelling-wave ion mobility spectrom-
etry (TWIMS) to determine the rotationally averaged collision 
cross-section (TWCCS N2→He) following drift time calibration.   
The charge state distribution of both WT and D274N Aur A fol-
lowing native MS was relatively compact (Fig. 2A, B), with 11+ 
and 12+ charge states of WT Aur A being observed predomi-
nantly. The 11+ ion was preferentially observed for D274N Aur 





yielded a broad TWCCS N2→He distribution for both protein spe-
cies (Fig. 2C, D), with the weighted average CCS value for non-
phosphorylated Aur A being marginally smaller (22.3 nm2) 
than that for the active phosphorylated Aur A (23.9 nm2) ki-
nase. However, the half-height width of the CCS distribution 
(CCSD) of inactive D274N Aur A was notably broader than that 
observed for the active enzyme, indicating greater conforma-
tional flexibility of the non-phosphorylated protein (Fig. 2E).  
Gaussian fitting of these CCS data revealed three overlapping 
conformers, with an additional fourth, larger conformational 
state of relatively low abundance that was fitted for D274N Aur 
A. For ease of comparison, these data are also presented as 
weighted distributions for each conformer (Supp. Fig. 2). The 
CCS and the CCSD values of the two predominant conformers 
(conformers II and III) for both proteins were within the 2% 
variance generally observed with these types of native IM-MS 
experiments (conformer II: CCS = 22.6 nm2, CCDS = 1.8 nm2; 
conformer III: CCS = 23.7 nm2, CCDS = 5.4 nm2), suggesting that 
these conformational states are likely to be analogous between 
active phosphorylated and inactive non-phosphorylated Aur A 
proteins. However, there was a clear difference in the relative 
abundance of conformers II and III for these two proteins, with 
the proportion of conformer II being much lower for the non-
phosphorylated D274N protein. Conformer I was slightly big-
ger for D274N Aur A than for phosphorylated WT protein (CCS 
= 20.2 nm2 and 20.9 nm2 for the WT and D274N proteins, re-
spectively), and was also a much more abundant component of 
the conformational space adopted by inactive Aur A. Con-
versely, the relative abundance of conformer II with respect to 
conformers I and III was lower in the inactive protein. Instead, 
we observed an additional configuration, conformer IV at 31.0 
nm2, exclusively for non-phosphorylated D274N Aur A. These 
initial observations suggest that phosphorylation of Aur A 
serves to partially constrain the conformational landscape that 
this protein can adopt, which is likely linked to successful sub-
strate binding and phosphotransfer.  
 
Modelling suggests that the major experimental conformers 
relate to open/closed states rather than different DFG motif 
conformations or activity 
In support of our experimental data, we used IMPACT to esti-
mate CCS values from several all-atom models of Aur A (122-
403), built to sympathetically add in missing parts of the pro-
tein chain to crystal structures of Aur A found in the protein 
databank (PDB). These structures include PDB codes 1OL7, 
5L8K, and 6HJK, as examples of different configurations of the 
activation loop (A-loop) with the DFG motif positioned as DFG-
in, DFG-up, and DFG-out, respectively (Fig. 2F, Supp. Table 1). 
One further modelled structure of note was PDB code 4C3P, 
where dephosphorylated Aur A was co-crystallised as a dimer 
in the presence of the activating TPX2 peptide, and in which the 
A-loop and the EF helix adopt an ‘open’ configuration, extend-
ing out from the rest of the kinase domain, and the DFG motif is 
positioned as DFG-in. Despite the difference in DFG/A-loop po-
sition, estimates of CCS values for these static structures—bar-
ring those for 4C3P—gave similar values, averaging 22.7, 22.9 
and 23.3 nm2 for the DFG-in, DFG-up, and DFG-out groups of 
structures, respectively (Supp. Table 1). These values are an ex-
cellent match for those determined experimentally for con-
former II or conformer III. The two 4C3P-derived models, with 
their ‘open’ A-loop structure, gave higher CCS values averaging 
24.9 nm2, in line with conformer III.  
To generate a dynamic picture of protein behaviour, molecular 
dynamics (MD) simulations were initiated from each of these 
structural models. Each simulation provides an ensemble of 
structures and yields a wider distribution of CCS values (Supp. 
Figure 2. Active hyperphosphorylated Aur A (122-403) is more 
conformationally compact than inactive non-phosphorylated Aur 
A. Native ESI mass spectrum of hyperphosphorylated active WT (A) or 
non-phosphorylated inactive D274N (B) Aur A (122-403). (C-E) 
TWCCSN2→He for the [M+11H] 11+ species of WT (C) or D274N (D) Aur A 
(122-403). The red line is the average of three independent replicates. 
Black error bars representing S.D.. Gaussian fitting was performed in 
Matlab (Version R2018a), with RMSD and R2 values listed. (E) Overlaid 
TWCCSN2→He for WT (red), D274N (blue) Aur A and an overall distribution 
from all-atom simulations (black). (F) Zoomed-in view showing the po-
sition of the Phe side-chain in select example crystal structures: DFG-in 
(black, 1OL7), DFG-up (green, 5L8K), DFG-out (blue, 6HJK). The ATP 
binding site is marked by an ADP molecule (orange) from 1OL7; this 
highlights the clash with the DFG-out Phe. (G)Overlay of crystal struc-
tures from 1OL7 (black) and 4C3P (red). Each 4C3P Aur A monomer ex-
hibits a displaced A-loop and αEF helix (coloured blue) compared to 






Fig. 3). When considered together, the CCS distributions resem-
ble those observed experimentally by IM-MS for conformers II 
and III, albeit with the two peak positions shifted up to ~24 nm2 
and ~26 nm2 (Fig. 2E, Supp. Fig. 3). This difference of 5–10% 
compared to the experimentally determined values is similar to 
the differences previously observed between experimental and 
IMPACT computed CCS values for other proteins (72). The dis-
tributions of exemplar DFG-in (1OL7), DFG-inter (5L8K) and 
DFG-out (6HJK) structures are virtually indistinguishable, 
whilst the higher CCS values are almost exclusively from the 
4C3P (DFG-in, A-loop open) simulations (Supp. Fig. 3B; Supp. 
Table 1). An analysis of the DFG motif conformation for every 
frame of the simulation trajectories shows that, in large part, 
the initial DFG-motif position is maintained within each simu-
lation (Supp. Fig. 4). Further interrogation of simulated struc-
tures (Supp. Fig. 5) suggests that experimental conformers II 
and III do not relate to different DFG-motif conformations. In-
stead, conformer II represents ‘closed’ kinase configurations, 
where the A-loop is inward facing, while conformer III repre-
sents the ‘open’ configurations, one example being the disloca-
tion of the A-loop and EF helix as observed in 4C3P. The broad 
CCSD of conformer III (Fig. 2C/D) suggests that this is likely 
made up of several different ‘open’ configurations that cannot 
be resolved, or possibly interconversion of different ‘open’ and 
‘closed’ configurations occurring within the timescale of the 
IMS experiment. 
Enhanced conformation sampling at the expense of chemical 
detail can be achieved through use of a much-simplified, struc-
ture-based ‘Gō-model’, where each residue is considered as a 
single ‘bead’ and the only stabilising interactions are those from 
contacts made in the initial structure (68). Individual Gō-model 
simulations based on the 1OL7 crystal structure gave rise to re-
producible CCS distributions that again match well with the ex-
perimental profile for conformers II and III (Fig. 2E, Supp. Fig 
6). Further analyses of the Gō-model simulated structures again 
suggest that conformer III could be composed of configurations 
with a mobile and extended A-loop, but also suggest a signifi-
cant contribution from configurations with a dynamically, un-
folding N-terminus. 
Interestingly, none of the MD simulations reveal conformations 
equivalent to either conformer I or conformer IV as observed 
by IM-MS, suggesting that these extremes in the conformational 
landscape may be either experimentally-induced structural 
compaction in the case of conformer I, or a specific configura-
tion of inactive Aur A that is not represented in the protein data 
bank (conformer IV). 
 
TPX2 binding alters the conformational landscape of both 
hyperphosphorylated and non-phosphorylated Aur A 
Binding of the minimal TPX2 peptide (1-43) to phosphorylated 
Aur A (122-403) has previously been shown to stabilise the ac-
tive conformation of Aur A in vitro, interacting with the N-ter-
minal lobe of Aur A (thereby stabilising the position of the C-
helix), and secondarily by stabilising the A-loop (73). We thus 
investigated the effect of a minimal TPX2 peptide that activates 
Aur A, on the conformational landscape of both the active and 
inactive forms of Aur A. Binding of the TPX2 peptide (1-43) to 
WT Aur A, which increased its activity (Fig. 3A), induced 
marked differences in its conformational landscape (Fig. 3B).  
Like unbound Aur A, Gaussian fitting of the CCS profile revealed 
four conformational states, which we termed I*, II*, III*, IV*.  
Although the mean weighted CCS values of the two smallest 
conformational states of WT Aur A are comparable (20.2, 22.6 
nm2 for I, II respectively, compared with 19.9, 22.3 nm2 for I*, 
II*), the conformational flexibility of these two states notably 
increased, as defined by approximate doubling of the CCSD val-
ues. Further evaluation of conformer II*, and noting the broad 
CCSD, suggests that this state may be representative of multiple 
conformations similar to those defined as II and III for unbound 
WT Aur A (Fig. 2C, Fig. 3B).  Given our hypothesis of conformers 
II and III representing ‘closed’ and ‘open’ configurations of 
(TPX2 unbound) WT Aur A, these data would suggest that TPX2 
binding lowers the barrier for switching between the ‘closed’ 
and ‘open’ states, changing the conformational equilibrium 
(and consequently making distinct states harder to distinguish 
by IM-MS). Furthermore, the fact that there is little difference 
in the overall CCS between these states in the presence of TPX2 
is in agreement with previous studies that reported no global 
conformation change due to TPX2 (peptide) binding, with TPX2 
docking into a (hydrophobic) groove in Aur A (24).  
 
Figure 3. Aur A-activating TPX2 peptide alters the conformational 
landscape of both hyper- and non-phosphorylated Aur A (122-
403). (A) In vitro peptide-based Aur A kinase assays using 5 µM WT or 
D274N Aur A in the presence of the minimal activating TPX2 peptide at 
the indicated concentrations; (B, C) TWCCSN2→He of the [M+11H]11+ spe-
cies of WT hyper-phosphorylated active (B) or D274N non-phosphory-
lated inactive (C) Aur A in the presence of 10-molar excess of the mini-
mal TPX2 peptide. The red line is the average of three independent rep-
licates. Black error bars represent the S.D.. Gaussian fitting was per-
formed in Matlab, with RMSD and R2 values listed.  
 
Interestingly, the two larger conformational states, III* and IV*, 
are distinct from anything observed for either WT or D274N 
Aur A, although the CCS for III* is similar to that generated fol-
lowing the IMPACT all atom simulation of 4C3P, the TPX2 
bound ‘DFG-in’ Aur A where the A-loop is open (Supp. Table 1; 





Binding of the TPX2 peptide to the inactive non-phosphory-
lated Aur A yielded two primary CCS distributions, fitting to 
three Gaussian peaks: II*, III* and IV*; conformer I* was not ob-
served. Supporting our hypothesis that conformer II* for TPX2-
WT Aur A represents a dynamic equilibrium between ‘open’ 
and ‘closed’ conformations, II* for D274N Aur A exhibited a 
much smaller CCSD (2.2 nm2 as opposed to 4.2 nm2 for WT Aur 
A) akin to that seen for unbound protein, as might be expected 
for inactive protein in a preferentially ‘closed’ configuration. 
 
Active hyperphosphorylated Aur A is less kinetically stable 
than inactive non-phosphorylated protein. 
To better understand relative differences in conformation sta-
bility of active hyper-phosphorylated Aur A compared with its 
inactive counterpart, we performed collision-induced unfold-
ing (CIU) experiments, comparing the CCS of WT versus D274N 
Aur A at different collision energies (CE) (Fig. 4). The applied 
CE was sufficient to promote protein unfolding, but not to in-
duce protein fragmentation.  
 
 
Figure 4. Active Aur A (122-403) is less kinetically stable than in-
active Aur A. Collision-induced unfolding profiles for the isolated 11+ 
charge state of WT (A) and D274N (B) Aur A (122-403) (or overlaid in 
(C)). Stepped collision energy was applied between 16 and 34 V in two-
volt intervals. Data analysis was carried out in MassLynx 4.1, (A, B) gen-
erating heat-maps using CIUSuite 2 and (C) mountain plots using Origin 
(Version 2016 64Bit). Presented are data from an average of 3 inde-
pendent experiments. 
 
Comparing CIU profiles in this manner provides information on 
the relative kinetic stabilities of the two proteins, as the acti-
vated ions generated at each stepped CE are trapped in a de-
fined conformational state (54, 74-77). Fig. 4A and B depict the 
CIU fingerprints for WT and D274N Aur A, respectively, and a 
direct comparison of the conformational landscapes adopted 
by these two proteins at each stepped CE value is presented in 
Fig. 4C. Four main CIU features were observed: the initial con-
formers (as represented in Fig. 2C, D), two partially unfolded 
intermediates (ranging from ~24–28 nm2), and final stable ‘un-
folded’ states between ~31-33 nm2 for active and inactive Aur 
A. Similar to the observed differences in conformational space 
adopted under native conditions, the final ‘unfolded’ inactive 
non-phosphorylated Aur A had a larger CCSD, indicative of 
greater conformational flexibility. It is also interesting to note 
that the CE required to initiate unfolding, and to transition be-
tween the partially unfolded intermediates, was lower for ac-
tive Aur A than was required for D274N (~24 V versus ~26 V 
respectively).  
Overall, these data point to the fact that active Aur A is less con-
formationally dynamic than Aur A in its non-phosphorylated in-
active form (albeit with a larger average CCS), and that it is mar-
ginally less stable than the inactive protein. This gas-phase ki-
netic stability data agrees with the liquid-phase thermostability 
data generated using DSF (Fig. 1C), where the Tm value (50% 
unfolding) was 41.7 °C for WT Aur A compared with 49.6 °C for 
D274N Aur A. Similar findings for solution stability have also 
been reported elsewhere (78, 79). 
 
Exposure to small molecule inhibitors alters the conforma-
tional distribution of active Aur A  
To investigate whether we are able to distinguish modes of 
small molecule binding to Aur A by IM-MS, we next evaluated 
the conformational profiles of active and inactive Aur A in the 
presence of a panel of Aur A inhibitors (Supp. Table 2, Fig. 5; 
Supp. Fig. 7). Based on a recent analysis, ENMD-2076 should fa-
vour a DFG-in mode, whereas MK-8745 is expected to favour a 
DFG-out mode. MLN8237 and VX-680 are believed to adopt a 
partial DFG-out position (47). We also investigated the struc-
tural effects induced in the presence of the generic type I pro-
tein kinase inhibitor staurosporine, which is almost always 
bound to kinases in a DFG-in conformation. The CCS/CCSD data 
for each of the (up to) four conformational states, as well as 
their relative proportion across the conformational landscape 
(as determined by Gaussian fitting of the CCS profiles for the 
inhibitor bound Aur A complexes and the proteins alone) are 
also depicted as proportional plots (Supp. Fig. 7), making dif-
ferences in the relative abundance of these conformational 
states (and their relative flexibility) easier to evaluate.  
While distinct from unbound active Aur A, the conformational 
landscapes observed upon binding of each of the Aur A inhibi-
tors was very similar, with comparable CCS and CCSD values for 
the (up to) 4 conformers defined by Gaussian fitting of the IMS  
profile. However, comparison with unbound active Aur A re-
vealed a trend towards increased abundance of conformer II 
relative to conformer III, for all inhibitor-bound forms, as well 
as a marked increase in the conformational flexibility of con-
former I (Fig. 2, Fig. 5, Supp. Fig. 7). Closer inspection of the CCS 
and CCSD values of conformers II and III across all conditions 
(Supp. Fig. 7A) reveals some notable differences in conformer 
III upon inhibitor binding. Not only do the dynamics of this con-
former appear to be slightly constrained in the presence of all 
five small molecules, with a reduction in CCSD from 5.4 nm2 to 
3.6-4.4 nm2, but there is also a ~5% increase in the average CCS. 





conformational landscape of hyperphosphorylated Aur A to-
wards a population of more discrete states – increasing the rel-
ative abundance of the compact ‘closed’ conformer II while de-
creasing the number of structural permutations underlying the 
slightly more ‘open’ configuration that we describe as con-
former III. 
 
Figure 5. IM-MS of inhibitor bound active and inactive Aurora A 
(122-403). TWCCSN2→He of the [M+11H] 11+ species of WT hyper-phos-
phorylated active (left) or D274N non-phosphorylated inactive (right) 
Aur A (122-403) in the presence of 10-molar excess of (A) MLN8237, 
(B) VX-680, (C) ENMD-2076, (D) MK-8745, or (E) staurosporine. The 
red line is the average of three independent replicates. Black error bars 
represent the S.D.. Gaussian fitting was performed in Matlab, with 
RMSD and R2 values listed.  
 
Comparison of the conformational states adopted by active Aur 
A bound to either of the two partial ‘DFG-out’ inhibitors, 
MLN8237 and VX-680 (Fig. 5A, B), as well as the DFG-in ENMD-
2076 (Fig. 5C) and DFG-out MK-8745 (Fig. 5D) inhibitors reveal 
minimal differences. A small increase (3-6%) in the relative 
abundance of conformer IV at ~30 nm2 was observed for 
MLN8237, VX-680 and ENMD-2076 (Supp. Fig. 7), whereas ev-
idence for this larger conformational state was absent for the 
MK-8745-bound protein.  
A much greater change was observed in the conformational to-
pology of active Aur A upon binding of the classical non-specific 
type I (DFG-in) inhibitor staurosporine, with the conforma-
tional landscape being constrained to conformers II and III (Fig. 
5E, Supp. Fig. 7). Although absent in the presence of staurospor-
ine, the smallest, and generally least-abundant conformational 
state (conformer I) is present for all other inhibitor-bound com-
plexes of WT Aur A, with a CCS of 19.7-19.9 nm2, similar to that 
observed for the unbound WT enzyme (Fig. 2C) at 20.2 nm2.  
Interestingly, the conformational landscapes adopted by 
D274N Aur A in the presence of inhibitors are notably different 
from each other, and when compared with active Aur A bound 
to the same small molecule. Of note, the relative abundance of 
conformer IV increased in all cases, with the exception of stau-
rosporine, where conformer IV is again absent. Conformer I, 
which accounts for ~7% of the conformational profile of un-
bound D274N Aur A was no longer observed, and the ratio of 
conformers II and III is variable (Fig. 5, Supp. Fig. 7). With re-
gard to staurosporine specifically, and in contrast to the other 
inhibitors, no difference was observed in the conformational 
landscape adopted by either WT or D274N Aur A.  
 
Active Aur A is stabilised to varying extents in the presence 
of different small molecule inhibitors 
The lack of marked differences in the conformational land-
scapes of active Aur A when bound to the different types of spe-
cific Aur A inhibitors prompted us to explore the kinetic stabil-
ity of these complexes by CIU (Fig. 6; Supp. Figs. 8, 9). 
As can be seen from the CIU profiles, the different inhibitors had 
pronounced effects on the relative kinetic stability of both ac-
tive and inactive Aur A. While the final stable ‘unfolded’ struc-
tures for all the inhibitor-bound forms of WT Aur A (recorded 
at 34 V) approached a CCS value of ~ 33–35 nm2, the energy 
required to initiate unfolding, and the conformational states 
adopted during unfolding were markedly different (Fig. 6, Supp 
Figs. 8, 9). Of all the inhibitors evaluated, the unfolding profile 
of MLN8237-bound Aur A (active and inactive) was most simi-
lar to that of the unbound protein (Fig. 6, Supp. Fig. 8). 
MLN8237 had little apparent effect on the kinetic stability of 
Aur A, as determined by the comparable CE required to induce 
unfolding. Notably, the CCS of the final unfolded conformation 
of MLN8237-bound Aur A was larger than for the unbound 
form, and the relative abundance of the partially unfolded tran-
sition states was lower (Fig. 6A, B; Supp. Fig 8), suggesting that 
the partially unfolded intermediate states were marginally less 
stable in the presence of MLN8237.  
Binding of the other partial DFG-out inhibitor, VX-680, induced 
a marked stabilisation of the active enzyme, requiring higher 
CE to initiate unfolding (Fig. 6C). Different (more compact) 
transition and final states (exhibiting reduced CCSD) were also 
observed for VX-680–Aur A compared with unbound protein, 
including a particularly stable partially unfolded intermediate 
at ~22.7 nm2. There was also some evidence of inhibitor-in-
duced compaction during CIU of WT Aur A, with species of CCS 
value <20 nm2 being observed (Fig. 6; Supp. Fig. 8).  
Both ENMD-2076 and MK-8745 transitioned from their native 
folded state to a stable ‘unfolded’ conformer with limited ob-
servable partially unfolded intermediates, albeit with major 
differences in the kinetic energy required to initiate the process 
(Fig. 6; Supp. Fig 8). ENMD-2076 induced the greatest stabilisa-





the original conformational states were retained in MK8745-
bound Aur A until ~30 V, transition to the final ‘unfolded’ state 
was evident by 24 V, with the protein simultaneously adopting 
two distinct configurations. This difference in unfolding topol-
ogy for Aur A in the presence of the DFG-out and DFG-in inhib-
itors was not apparent for the inactive D274N Aur A. Indeed, 
the CIU profiles for inactive Aur A with either ENMD-2076 or 
MK-8745 (or staurosporine) were essentially identical.  
  
Figure 6. Collision-induced unfolding profiles of inhibitor bound 
Aur A. The isolated 11+ charge state of (A) WT (left) and D274N (right) 
Aur A (122-403) in the presence of 10-molar excess of (B) MLN8237, 
(C) VX-680, (D) ENMD-2076, (E) MK-8745, or (F) staurosporine were 
subject to CIU using a stepped collision energy between 16 and 34 V 
(two-volt intervals). Data analysis was carried out in MassLynx 4.1, 
(generating heat-maps using CIUSuite 2). Presented are data from a sin-
gle experiment, representative of the data from independent triplicate 
analyses. 
 
Comparative thermal stability profiling of unbound versus in-
hibitor-bound hyperphosphorylated Aur A by DSF (Fig. 7) re-
vealed similar unfolding profiles for WT Aur A in the presence 
of MLN8237, VX-680 or MK-8745, with an increase in Tm of >7.5 
°C.  ENMD-2076 and staurosporine induced slightly greater sta-
bilisation, with a ΔTm of >9.2°C. In the case of MLN8237, alt-
hough we observed thermal stabilisation, there was little differ-
ence in the kinetic energy required to initiate unfolding as de-
termined by CIU. However, the CE required to reach the final 
stable ‘unfolded’ configuration of WT Aur A was higher when it 
was bound to MLN8237, suggesting that Tm measurements are 
likely more representative of the energy required to reach a 
stable unfolded state. This hypothesis holds true for all inhibi-
tor bound forms of WT Aur A, with the exception of VX-680, but 
not for inhibitors bound to inactive Aur A. While ΔTm values as-
sociated with inhibitor-bound D274N Aur A were relatively 
small (~<2.5 °C) (Fig. 7), protein unfolding required higher CE 
for all bound forms. Indeed, with the exception of MK-8745, 
there was little difference in unfolding profiles, and the CE re-
quired to induce unfolding for a given inhibitor, between active 
hyperphosphorylated, and inactive non-phosphorylated Aur A 
(Fig. 6, Supp Fig. 8), as exemplified by the comparison of the ex-
tracted partially unfolded profiles obtained at a CE of 26 V 
(Supp. Fig. 9) [78, 80, 81].  
 
Figure 7. Inhibitor-induced complexation stabilises both catalyti-
cally active and inactive Aur A. (A) DSF thermal stability assay with 
5 µM Aur A + 4% DMSO (black), in the presence of 40 μM of each inhib-
itor. (B) Difference in melting temperature (ΔTm) relative to 4% DMSO 






Discussion and Conclusions 
In this study, we exploited IM-MS to explore changes and differ-
ences in the conformational landscape dynamics of purified Aur 
A existing in both active (phosphorylated) and inactive (non-
phosphorylated) forms. For the first time, we also examined the 
effect of an activating TPX2 peptide on Aur A structural dynam-
ics, and evaluated the effects of different classes of small mole-
cule Aur A inhibitors. Gaussian fitting of our IM-MS data reveals 
up to four conformational states for Aur A, subtle variations in 
which (such as their relative ratio, CCS and CCSD) are found to 
be dependent on Aur A activation status, which is previously 
been shown to correlate with T-loop phosphorylation on 
Thr288. The active hyperphosphorylated form of Aur A gener-
ally exhibits slightly reduced conformational dynamics and re-
duced stability than the catalytically-inactive protein (Figs. 1 & 
2), as determined by both DSF thermal stability and CIU IM-MS 
experiments. Consistently IM-MS determination of the rota-
tionally averaged collision cross section of active Aur A was fur-
ther supported by molecular modelling approaches.  
Based on evaluation of i) the ratio of conformers II and III 
across the conditions analysed; ii) the generally broad CCSD of 
conformer III, suggestive of extensive dynamics, and/or over-
lapping conformational states that could not be resolved by 
IMS; iii) the shift to a notably higher CCS and smaller CCSD be-
tween conformers III and III* for WT Aur A in the absence and 
presence of the activating TPX2 peptide; and iv) CCS distribu-
tions generated from molecular simulations of Aur A in differ-
ent conformations being consistent with the experimental pro-
files for conformers II and III, we propose that conformer II (at 
~23 nm2) is representative of ‘closed’ structural states (be they 
DFG-in/up/out), where the A-loop is inward facing, while con-
former III represents one or more ‘open’ kinase configurations 
where the A-loop extends out. 
At the outset of this study, we hypothesised that the activation 
status of Aur A, and the binding of different classes of small mol-
ecule inhibitor would alter the conformational landscape 
adopted by this protein, as has been established previously (78, 
80, 81), e.g. with other protein kinases such as PKA (54, 82), c-
Abl (83) and FGFR1 (84), as well as intrinsically disordered 
proteins such as p53 (13, 85) and Aβ40 (86).  While we do in-
deed see some differences, the effects are subtler than might be 
anticipated, being broadly consistent with the findings of oth-
ers (80, 81). Interestingly, all inhibitors increased the ratio of 
the ‘closed’ conformer II relative to III, with a concomitant in-
crease in the CCS of the third conformational state. However, 
inhibitor-specific structural effects that have previously been 
shown to alter the position of the DFG loop using X-ray crystal-
lography, were hard to detect in the gas phase using IMS.   
CIU analysis went some way to start to unravel specific inhibi-
tor-induced differences; although all inhibitors stabilised Aur A 
with respect to unfolding (as confirmed in solution by DSF) and 
this effect was most marked with the DFG-in inhibitor ENMD-
2076, and the partial DFG-up/inter inhibitor VX-680 (Fig. 6, 
Supp. Fig. 8), as can be seen most clearly when we consider the 
difference in conformational profiles at mid-unfolding in the 
snapshot taken at CE of 26 V (Supp. Fig. 9). 
Overall, our CIU experiments indicate that all the inhibitors 
evaluated resulted in kinetic stabilisation of Aur A, given that 
higher collision energy was required to initiate unfolding, with 
this effect being least apparent with MLN8237, and highest 
with ENMD-2076 and VX-680 (Fig. 5, Supp. Fig. 2). More inter-
estingly, by application of CIU we were able to observe differ-
ences in the relative kinetic stability of Aur A when bound to 
the partial DFG-out inhibitors, as opposed to either a DFG-in or 
a DFG-out inhibitor. Notably, the partially unfolded transition 
states observed for active Aur A alone or in the presence of ei-
ther MLN8237 or VX-680 were absent with the other small mol-
ecules (Fig. 6) suggesting that these partial DFG-out inhibitors 
function to ‘lock’ Aur A into specific configurations. The effects 
of binding of these two partial DFG-out inhibitors to Aur A are 
thus likely not only a function of the position of the DFG/P-loop, 
but also reliant on the precise nature of the non-covalent inter-
actions mediated by different chemical classes. We cautiously 
interpret this finding in the context of the DFG-up confor-
mation, which has been observed with MLN8054 and VX-680 in 
complex with Aur A (PDB codes 2X81, 2WTV and 4JBQ, respec-
tively). Finally, we anticipate that future studies employing IM-
MS and CIU may prove useful in helping to define the mode of 
action of other small molecule Aur A inhibitors, and in the char-
acterisation of the conformational space adopted by other 
druggable enzymes, including the >500 members of the human 
kinome. How this conformational space changes upon binding 
to a variety of protein and chemical ligands also has potential 
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